12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers
PLx Pharma (NASDAQ:PLXP) stock increased by 15.5% to $0.7 during Monday's pre-market session. The market value of their outstanding shares is at $20.3 million.
Why Quanergy Systems Shares Are Trading Sharply Lower; Here Are 28 Stocks Moving Premarket
Gainers
Selina Hospitality PLC (NASDAQ: SLNA) rose 31.9% to $19.90 in pre-market trading after dipping around 63% on Friday.
FDA’s AdComm Gives Thumbs Down To Pediatric Cancer Therapy
FDA's Oncologic Drugs Advisory Committee (ODAC) raised concerns regarding the efficacy of Y-mAbs Therapeutics Inc's (NASDAQ: YMAB) potential pediatric neuroblastoma treatment, omburtamab.
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Gainers
UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also reported better-than-expected Q3 sales results.
Why UserTesting Shares Are Trading Higher By Around 93%? Here Are 53 Stocks Moving In Thursday’s Mid-Day Session
Gainers
HeartCore Enterprises, Inc. (NASDAQ: HTCR) gained 111% to $2.03 after the company announced it entered into a license agreement with Transcosmos Digital Technology for its Apromore process mining tool.
Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday
Gainers
ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate Cancer Foundation Scientific Retreat.
Y-mAbs Highlights Presentation Of Pivotal Data For Omburtamab
Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic
AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.
Y-MAbs Therapeutics Announces Regulatory Filing For DANYELZA In Brazil
NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (("Y-mAbs", NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel,